Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
Acetaminophen// 4.prime.-Hydroxyacetanilide// N-(4-Hydroxyphenyl)acetamide// Paracetamol	(mg/L)		(168.5 - 216.7)		(132.9 - 154.6)	1.3	1.33		0.628
Acetone// 2-Propanone// Dimethyl ketone	(%v/v)		(2.02 - 2.45)		(1.08 - 1.32)	1.7	1.70		0.653
2-Acetylaminofluorene// 2-AAF// 2-Acetamidofluorene// N-2-Fluorenylacetamide	(mg/L)		(86.0 - 91.0)		(6.75 - 7.65)	12.4	12.38		
Acetylhydrazide; Acetic acid hydrazide; Monoacetyl hydrazine	(mg/mL)	12.42	(12.16-12.68)	0.04	(0.03-0.09)	310.5	310.5	0.04	0.003
Acrylamide// 2-Propenamide	(mg/mL)	0.157	(0.144 - 0.170)	0.063	(0.056 - 0.069)	2.51	2.5	0.042	0.27
Acrylamide// 2-Propenamide	(mg/mL)	0.269	(0.101 - 0.437)	0.057	(0.050 - 0.063)	4.68	4.7	0.100	0.372
Acrylamide// 2-Propenamide	(mg/mL)	0.223	(0.180 - 0.266)	0.040	(0.029 - 0.051)	5.56	5.6	0.015	0.067
Actinomycin D// Dactinomycin// Cosmegen (Merck & Co.)	(mg/mL)	1.89	(1.38-2.61)	2.17	(1.88-2.51)		0.87	1.59	0.841
Aldoxycarb//aldicarb sulfone//sulfocarb//2-methyl-2-(methylsulfonyl)propanol O-((methylamino)carbonyl) oxime	(mg/L)	100		97.3	(92.1-102.5)		1.03	100	1
Aliphatic natural petroleum crude (90% aqueous extract) (CRM-5)						1			

Substance	FETAX Malformations	Reference
Acetaminophen// 4.prime.-Hydroxyacetanilide// N-(4-Hydroxyphenyl)acetamide// Paracetamol		Fort et al. (1992)
Acetone// 2-Propanone// Dimethyl ketone		Rayburn et al. (1991)
2-Acetylaminofluorene// 2-AAF// 2-Acetamidofluorene// N-2-Fluorenylacetamide		Fort et al. (1989)
Acetylhydrazide; Acetic acid hydrazide; Monoacetyl hydrazine		Fort and Bantle (1990)
Acrylamide// 2-Propenamide	Se between 96h EC50 and 96h LC50; AE, AO, Se, OE, PE, FA, OC, SG, Tc at 96h EC50	Bantle et al. (1998? rpt)
Acrylamide// 2-Propenamide	Se between 96h EC50 and 96h LC50; AE, AO, Se, OE, PE, FA, OC, SG, Tc at 96h EC50	Bantle et al. (1998? rpt)
Acrylamide// 2-Propenamide	Se between 96h EC50 and 96h LC50; AE, AO, Se, OE, PE, FA, OC, SG, Tc at 96h EC50	Bantle et al. (1998? rpt)
Actinomycin D// Dactinomycin// Cosmegen (Merck & Co.)		Courchesne, CL, and JA Bantle
Aldoxycarb//aldicarb sulfone//sulfocarb//2-methyl-2-(methylsulfonyl)propanol O-((methylamino)carbonyl) oxime	mal-developed gut, visceral and pericardial edema, notochord defects	Bantle et al. (1990)
Aliphatic natural petroleum crude (90% aqueous extract) (CRM-5)	No observed effects, 100% growth	Dawson et al. (1991)

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
Amaranth// FD&C Red No. 2	(mg/L)	3387	(3069-3727)	3500	(3258-4126)	3.4	0.97	3583	1.058
Aminobenzoic acid hydrazide	(mM)				(0.265 - 0.394)	24			
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide	(mg/mL)	1.98		0.0048		412.5	410	1.07	0.540
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide	(mg/mL)	2.79		0.0045		620.0	620	1.14	0.409
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide	(mg/mL)	2.05		0.0037		554.1	550	1.60	0.780
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide	(mg/mL)	2.25		0.0052		432.7	430	1.07	0.476
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide	(mg/mL)	1.86		0.0077		241.6	240	1.600	0.860
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide	(mg/mL)	2.54		*		*	*	1.600	0.630
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide	(mg/mL)	2.14		0.0046		465.2	470	0.004	0.002
.beta.-Aminopropionitrile	(mg/L)	79.37		0.07		1221.0	1100	908	0.001

* An EC50 could not be calculated because information did not occur in the concentration range tested. The TI values were only calculated from mean LC50 and EC50 values.

Substance	FETAX Malformations	Reference
Amaranth// FD&C Red No. 2	Gm, PE at conc. > 2500 mg/L and 4500 mg/L respect.; Gm, CF, MD at conc. > 6000 mg/L; Mk at ocnc. > 9000 mg/L	Bantle et al. (1994a)
Aminobenzoic acid hydrazide		Bantle et al. (1994a)
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide		Bantle et al. (1994a)
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide		Bantle et al. (1994a)
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide		Bantle et al. (1994a)
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide		Bantle et al. (1994a)
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide		Bantle et al. (1994a)
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide		Bantle et al. (1996)
6-Aminonicotinamide// 6-Amino-3-pyridinecarboxamide		Bantle et al. (1996)
.beta.-Aminopropionitrile		Bantle et al. (1996)
* An EC50 could not be calcula LC50 and EC50 values.		

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
.beta.-Aminopropionitrile	(mg/L)	29.43		0.30		97.9	122.625	11.73	0.3986
.beta.-Aminopropionitrile	(mg/L)	4.17		0.93		4.5	4.48	0.33	0.079
.beta.-Aminopropionitrile	(mg/L)	40.53		1.15		35.4	35.24	0.45	0.011
.beta.-Aminopropionitrile	(mg/L)	4.90		0.69		7.1	7.10	0.00133	0.000271
.beta.-Aminopropionitrile	(mg/L)	7.93		0.20		40.1	39.65	0.20	0.03
.beta.-Aminopropionitrile	(mg/L)	77.00		1.07		72.2	71.96	0.67	0.0087
p-Anisic acid hydrazide	(mM)		(6.18 - 10.05)		(0.07 - 0.093)	95	95.625		
Aromatic natural petroleum crude (CRM 3)		33.38		31.10		1.1	1.07		
Ascorbic acid// L-Ascorbic acid// Vitamin C	(mg/L)	19.70	(18.47-20.97)	12.1	(11.0-13.43)	1.63	1.63	10	0.508
Ascorbic acid// L-Ascorbic acid// Vitamin C	(mg/L)	10.98		6.60		1.7	1.66	8.33	0.759
Ascorbic acid// L-Ascorbic acid// Vitamin C	(mg/L)	13.06		6.29		2.1	2.08	2.67	0.204
Ascorbic acid// L-Ascorbic acid// Vitamin C	(mg/L)	14.83		4.60		1.3	1.274	3.33	0.223
Ascorbic acid// L-Ascorbic acid// Vitamin C	(mg/L)	1.82		0.74		2.5	2.5	0.37	0.020
Ascorbic acid// L-Ascorbic acid// Vitamin C	(mg/L)	9.91		7.43		1.3	1.33	8.33	0.841

Substance	FETAX Malformations	Reference
.beta.-Aminopropionitrile		Bantle et al. (1996)
.beta.-Aminopropionitrile		Bantle et al. (1996)
.beta.-Aminopropionitrile		Bantle et al. (1996)
.beta.-Aminopropionitrile		Bantle et al. (1996)
.beta.-Aminopropionitrile		Dawson et al. (1991)
.beta.-Aminopropionitrile		Bantle et al. (1996)
p-Anisic acid hydrazide		Bantle et al. (1996)
Aromatic natural petroleum crude (CRM 3)	90% growth	Bantle et al. (1996)
Ascorbic acid// L-Ascorbic acid// Vitamin C		Bantle et al. (1996)
Ascorbic acid// L-Ascorbic acid// Vitamin C		Bantle et al. (1996)
Ascorbic acid// L-Ascorbic acid// Vitamin C		Bantle et al. (1996)
Ascorbic acid// L-Ascorbic acid// Vitamin C		Bantle et al. (1996)
Ascorbic acid// L-Ascorbic acid// Vitamin C		Bantle et al. (1990)
Ascorbic acid// L-Ascorbic acid// Vitamin C		Bantle et al. (1990)

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
Ascorbic acid// L-Ascorbic acid// Vitamin C	(mg/L)	13.61		13.03		1.0	1.04	14.67	1.078
Aspartame// asp-phe methyl ester	(mg/L)	10000	(> 10000)	10000	(> 10000)	1.0	1.00	3000	0.300
Aspartame// asp-phe methyl ester	(mg/L)	10000	(> 10000)	10000	(> 10000)	1.0	1.00	7000	0.700
Aspartame// asp-phe methyl ester	(mg/L)		(11928 - 16234)		(10951 - 15788)	1.1	1.06	7000	0.503
Atrazine	(mg/L)					3.0	3.03		0.110
5-Azacytidine// Azacitidine// 4-Amino-1-.beta.-D-ribofuranosyl-1,3,5-triazin-2(1H)-one	(mg/L)	620	(587 - 658)	50		12.4	12.4	400	0.645
5-Azacytidine// Azacitidine// 4-Amino-1-.beta.-D-ribofuranosyl-1,3,5-triazin-2(1H)-one	(mg/L)	600	(563 - 643)	70	(62.0 - 72.0)	8.6	8.57	100	0.167
5-Azacytidine// Azacitidine// 4-Amino-1-.beta.-D-ribofuranosyl-1,3,5-triazin-2(1H)-one	(mg/L)	430	(382 - 469)	20	(19.0 - 24.0)	21.5	21.5	70	0.163
Benzo[a]pyrene	(mg/L)	10	(-----)		(7.0 - 16.0)	0.9	1.00		
Benzoyl Hydrazine	(mg/L)		(619.70 - 730.63)		(79.08 - 93.57)	7.9	7.87		
Bisphenol A//4,4'-(1-methylpropylidene) bisphenol//4,4'-isopropylidenediphenol	(mg/L)	50		35.1	(29.1-41.1)		1.42	40	0.800

Substance	FETAX Malformations	Reference
Ascorbic acid// L-Ascorbic acid// Vitamin C		Bantle et al. (1990)
Aspartame// asp-phe methyl ester		Morgan et al. (1996)
Aspartame// asp-phe methyl ester		Bantle et al. (1990)
Aspartame// asp-phe methyl ester		Bantle et al. (1990)
Atrazine		Bantle et al. (1990)
5-Azacytidine// Azacitidine// 4-Amino-1-.beta.-D-ribofuranosyl-1,3,5-triazin-2(1H)-one	Gm, MD at conc. > 30 mg/L; Mk, VE, ME at conc. > 70 mg/L; MO, CF at conc. > 100 mg/L	Propst et al. (1997)
5-Azacytidine// Azacitidine// 4-Amino-1-.beta.-D-ribofuranosyl-1,3,5-triazin-2(1H)-one	Gm, MD at conc. > 30 mg/L; Mk, VE, ME at conc. > 70 mg/L; MO, CF at conc. > 100 mg/L	Riggin and Schultz (1986)
5-Azacytidine// Azacitidine// 4-Amino-1-.beta.-D-ribofuranosyl-1,3,5-triazin-2(1H)-one	Gm, MD at conc. > 30 mg/L; Mk, VE, ME at conc. > 70 mg/L; MO, CF at conc. > 100 mg/L	Bantle et al. (1998? rpt)
Benzo[a]pyrene		Bantle et al. (1998? rpt)
Benzoyl Hydrazine		Bantle et al. (1998? rpt)
Bisphenol A//4,4'-(1-methylpropylidene) bisphenol//4,4'-isopropylidenediphenol	mal-developed gut, craniofacial defects, mal-development of the mouth	Bantle et al. (1998? rpt)

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
Boric Acid	(mg/mL)	1.162	(0.955 - 1.369)	0.512	(0.461 - 0.562)	2.263	22.7	0.400	0.344
Boric Acid	(mg/mL)	1.113	(1.009 - 1.216)	0.189	(0.152 - 0.226)	5.950	5.89	0.100	0.0898
Boric Acid	(mg/mL)	0.660	(0.309 - 1.011)	0.343	(0.169 - 0.517)	1.930	1.92	0.172	0.261
4-Bromobenzene	(mg/L)		(1450.0 - 3410.0)		(190.0 - 370.0)	10	10	500	0.179
t-Butylcarbazate	(mmoles/L)		(17.94 - 24.29)		(0.24 - 0.30)	77	77.44		
2-Butyn-1-ol	(mmol/L)		(14.3 - 35.7)		(0.7 - 1.4)	34.4	34.39		
3-Butyn-1-ol	(mmol/L)		(3.6 - 7.1)		(1.4 - 3.6	2.5	2.51		
3-Butyn-2-ol	(mmol/L)		(0.7 - 0.9)			1.1	1.06		
2-Butyne-1,4-diol	(mmol/L)		(58.1 - 63.9)		(2.9 - 5.8)	10.3	10.31		
Cadmium chloride	(.mu.mol/L)					8.6	8.65		0.563
Caffeine	(mg/mL)	0.35		0.110		3.2	3.7	0.07	0.20

Substance	FETAX Malformations	Reference
Boric Acid	LS, Mo at some conc.; Sl, OC(s), Gm, at MAS 96h EC50; AE, Mo, Se at MAS 96h LC50; AO, SG, OE at higher conc.; TB in some embryos	Dawson et al. (1991)
Boric Acid	LS, Mo at some conc.; Sl, OC(s), Gm, at MAS 96h EC50; AE, Mo, Se at MAS 96h LC50; AO, SG, OE at higher conc.; TB in some embryos	Dawson et al. (1990)
Boric Acid	LS, Mo at some conc.; Sl, OC(s), Gm, at MAS 96h EC50; AE, Mo, Se at MAS 96h LC50; AO, SG, OE at higher conc.; TB in some embryos	Dawson et al. (1990)
4-Bromobenzene		Dawson et al. (1990)
t-Butylcarbazate		Dawson et al. (1990)
2-Butyn-1-ol		Sunderman et al. (1991)
3-Butyn-1-ol		Bantle et al. (1994b)
3-Butyn-2-ol		Bantle et al. (1994b)
2-Butyne-1,4-diol		Bantle et al. (1994b)
Cadmium chloride		Bantle et al. (1994b)
Caffeine		Bantle et al. (1994b)

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
Caffeine	(mg/mL)	0.41		0.13		3.10	3.2	0.13	0.32
Caffeine	(mg/mL)	0.91		0.11		8.65	8.3	0.12	0.13
Caffeine	(mg/mL)	0.61		0.13		4.92	4.7	0.10	0.16
Caffeine	(mg/mL)	0.52		0.15		3.40	3.5	0.18	0.35
Caffeine	(mg/mL)	0.44		0.15		2.87	2.9	0.10	0.22
Caffeine	(mg/mL)	0.62		0.16		3.94	3.9	0.10	0.16
Caffeine	(mg/mL)	0.27		0.107		2.5	2.5	0.09	0.3
Caffeine	(mg/mL)	0.257	(0.21 - 0.31)	0.128	0.12 - 0.14)	2.01	2.01	0.1	0.389
Caffeine	(mg/mL)	0.24		0.093		2.6	2.6	0.06	0.3
Caffeine	(mg/mL)	0.25		0.074		3.4	3.4	0.05	0.2
Caffeine	(mg/mL)	0.28		0.158		1.8	1.8	0.08	0.3
Caffeine	(mg/mL)	0.28		0.121		2.3	2.3	0.08	0.3
Caffeine	(mg/mL)	0.26		0.137		1.9	1.9	0.08	0.3
Catechol	(mg/L)		(12.6 - 14.1)		(2.5 - 2.9)	4.93	4.93	5	0.376
.alpha.-Chaconine	(mg/L)	3.9	(3.65-4.20)	2.85	(2.25-3.65)	1.4	1.37	3.35	0.859

Substance	FETAX Malformations	Reference
Caffeine		Bantle et al. (1994b)
Caffeine		Bantle et al. (1994b)
Caffeine		Bantle et al. (1994b)
Caffeine		Bantle et al. (1994b)
Caffeine		Bantle et al. (1994b)
Caffeine		Dawson and Bantle (1987)
Caffeine		Phase III-2
Caffeine	Mk, DB at just above the 96h EC50 but below the 96h LC50	Phase III-2
Caffeine		Phase III-2
Caffeine		Phase III-2
Caffeine		Friedman et al (1991)
Caffeine		Rayburn et al. (1994)
Caffeine		Rayburn et al. (1994)
Catechol		Rayburn et al. (1994)
.alpha.-Chaconine		Fort et al. (1991)

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
.beta.1-Chaconine	(.mu.mol/L)		(0.0038 - 0.0049)		(0.0021 - 0.0029)	1.72	1.72		1.326
.beta.2-Chaconine	(.mu.mol/L)	0.014			(0.0084 - 0.010)	1.5	1.52		0.607
.gamma.-Chaconine	(.mu.mol/L)	0.018			(0.0125 - 0.0156)	1.2	1.29		0.394
4-Chlorobenzoic acid hydrazide	(mM)		(1.60 - 0.323)		(0.073 - 0.084)	28	28.21		
Coal gasifier electrostatic precipitator tar (CRM-4)		0.83		0.48		1.7	1.73		
Coal-derived fuel oil blend (CRM 1)		1.48		0.96		1.54	1.54		
Cobalt chloride// Cobaltous chloride		10.4	(10.0 - 10.8)	25	(23 - 27)	416	0.416		
Copper (1)	(mg/L)	0.98	(0.92-1.08)	0.88	(0.80-0.99)	1.11	1.11	0.75	0.8522
Copper (2)	(mg/L)	0.89	(0.80-0.94)	0.74	(0.68-0.82)	1.20	1.20	0.75	0.8427
Copper chloride// Cupric chloride	(.mu.mol/L)					8.8	8.8		0.455

Substance	FETAX Malformations	Reference
.beta.1-Chaconine		
.beta.2-Chaconine		Luo et al. (1993)
.gamma.-Chaconine		
4-Chlorobenzoic acid hydrazide		Bantle et al. (1996)
Coal gasifier electrostatic precipitator tar (CRM-4)	pigmentation and motility reduction	Bantle et al. (1996)
Coal-derived fuel oil blend (CRM 1)	pigmentation and motility reduction	Bantle et al. (1996)
Cobalt chloride// Cobaltous chloride		Bantle et al. (1996)
Copper (1)	miscoiling of the gut (>0.25 mg/L); craniofacial abnormalities, maldevelopment of the eye, and nicroencephaly (>0.75 mg/L); defects of notochord development and visceral hemorrhage (>1.0 mg/L)	Bantle et al. (1996)
Copper (2)	miscoiling of the gut (>0.25 mg/L); craniofacial abnormalities, maldevelopment of the eye, and nicroencephaly (>0.75 mg/L); defects of notochord development and visceral hemorrhage (>1.0 mg/L)	Bantle et al. (1996)
Copper chloride// Cupric chloride		Bantle et al. (1996)

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
Copper sulfate	(mg/L)	0.98	(0.92 - 1.08)	0.88	(0.80 - 0.99)	1.11	1.11	0.75	0.765
Copper sulfate	(mg/L)	0.46		0.20		2.3	2.3	0.04	0.09
Copper sulfate	(mg/L)	2.17		2.68		0.8	0.8	0.92	0.42
Copper sulfate	(mg/L)	0.88		0.79		1.1	1.1	0.20	0.23
Copper sulfate	(mg/L)	1.93		1.10		1.8	1.75	0.43	0.22
Copper sulfate	(mg/L)	0.89	(0.80 - 0.94)	0.74	(0.68 - 0.82)	1.2	1.20	0.75	0.843
Copper sulfate	(mg/L)	1.32	(1.28 - 1.36)	0.97	(0.94 - 1.00)	1.36	1.36	1.13	0.856
Copper sulfate	(mg/L)	1.56		0.28		5.6	5.6	0.57	0.37
Copper sulfate	(mg/L)	0.77		0.20		3.8	3.9	0.27	0.35
Copper sulfate	(mg/L)	0.85		0.45		1.9	1.9	0.04	0.05
Cotinine	(mg/mL)		(4.12 - 4.56)		(0.61 - 0.86)	6.05	6.03		0.075
Coumarin	(mg/L)		(0.135 - 0.145)	0.042	(0.031 - 0.057)	3.23	3.45		0.228
Cycloheximide	(mg/mL x10 -4)		(1.03 - 2.34)		(1.01 - 1.40)		1.34		0.352
Cyclophosphamide	(mg/mL)	8.25		5.64		1.52	1.46	5.67	0.687
Cyclophosphamide	(mg/mL)	9.14		3.91		2.34	2.34	5.00	0.328
Cyclophosphamide	(mg/mL)	7.39		5.00		1.47	1.48	3.00	0.406

Substance	FETAX Malformations	Reference
Copper sulfate	severe at high concentrations; Gm at > 0.25 mg/L; CF, ME, RP at > 0.75 mg/L; NM, VH at > 1.0 mg/L	Fort et al. (1995)
Copper sulfate		Fort et al. (1995)
Copper sulfate		Fort et al. (1996)
Copper sulfate		Dawson et al. (1988b)
Copper sulfate		DeYoung et al. (1991)
Copper sulfate	severe at high concentrations; Gm at > 0.25 mg/L; CF, ME, RP at > 0.75 mg/L; NM, VH at > 1.0 mg/L	Courchesne, CL, and JA Bantle
Copper sulfate		Phase III-2
Copper sulfate		Phase III-2
Copper sulfate		Phase III-2
Copper sulfate		Phase III-2
Cotinine		Phase III-2
Coumarin		Phase III-2
Cycloheximide		Phase III-2
Cyclophosphamide		Fort et al. (1989)
Cyclophosphamide		Courchesne, CL, and JA Bantle
Cyclophosphamide		

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
Cyclophosphamide	(mg/mL)	7.33		4.93		1.54	1.49	3.00	0.409
Cyclophosphamide	(mg/mL)	6.28		4.88		1.29	1.29	4.33	0.689
Cyclophosphamide	(mg/mL)	6.27		4.92		1.27	1.27	3.00	0.478
Cyclophosphamide	(mg/mL)	7.00		5.19		1.35	1.35	4.67	0.667
Cyclophosphamide		8		6.2			1.30		
Cytochalasin D	(ng/mL)		(344.5 - 618.5)		(81.5 - 184.5)	3.9	3.81		
Cytosine arabinoside// Cytarabine	(mg/mL)		(4.51 - 6.48)		(0.63 - 0.93)		7.12		0.148
Desisopropyl atrazine	(mg/L)	93.3	(84.2-102.4)	29.40	(19.2-39.6)		3.17	30.00	0.320
Diazepam// Valium// 7-Chloro 1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one	(mg/mL)					1.8	1.78		
Dichloroacetate	(mg/mL)	9.22	(8.85 - 9.59)	8.19	(7.09 - 9.29)	1.13	1.13	5.25	0.569
Dichloroacetate	(mg/mL)	6.57	(6.41 - 6.73)	1.88	(1.19 - 2.57)	3.81	3.49	3.08	0.469
Dichloroacetate	(mg/mL)	7.03	(6.36 - 7.69)	5.15	4.00-630	1.38	1.37	6.51	0.926
Dichloroacetic acid	(mg/L)		(3900.0 - 5600.0)		(2400.0 - 4680.0)	1.1	1.14		1.153

Substance	FETAX Malformations	Reference
Cyclophosphamide		Bantle et al. (1998? rpt)
Cyclophosphamide		Bantle et al. (1998? rpt)
Cyclophosphamide		Bantle et al. (1998? rpt)
Cyclophosphamide		Bantle et al. (1998? rpt)
Cyclophosphamide		Fort et al.(1993)
Cytochalasin D		Morgan et al. (1996)
Cytosine arabinoside// Cytarabine		Bantle et al. (1998? rpt)
Desisopropyl atrazine	notochord defects, microencephaly, visceral edema, heart mal-development	Bantle et al. (1998? rpt)
Diazepam// Valium// 7-Chloro 1-methyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one		Bantle et al. (1998? rpt)
Dichloroacetate		Rayburn et al. (1991)
Dichloroacetate		
Dichloroacetate		
Dichloroacetic acid		Dawson and Bantle (1987)

Substance	Units	96-hr LC50	96-hr LC50 C.I.	96-hr EC50	96-hr EC50 C.I.	TI (provided)	TI (calculated)	MCIG	MCIG/LC50
2,4-D// 2,4-dichlorophenoxyacetic acid	(mg/L)					1.04	1.04		0.890
Diethylene glycol	(mg/mL)	30.03	(28.92 - 31.14)	18.74	(16.33 - 21.14)	1.61	1.60	13.33	0.444
Diethylene glycol	(mg/mL)	39.88	(31.36 - 48.41)	17.47	(16.85 - 18.08)	2.28	2.28	18.67	0.468
Diethylene glycol	(mg/mL)	32.48	(30.22 - 34.75)	9.74	(6.70 - 12.78)	3.50	3.33	3.37	0.104
Dimethyl sulfoxide// DMSO	(%v/v)		(1.59 - 2.04)		(1.13 - 1.54)	1.4	1.38		0.827
Diphenhydramine hydrochloride// Benadryl [registered]	(mg/mL)					10.7	10.33		0.097
Diphenylamine//N-phenylbenzeneamine	(mg/L)	100		39.60	(31.2-47.0)		2.53	50.00	0.500
Doxylamine succinate	(mg/L)		(132.5 - 138.5)		(0.375 - 0.44)	335.1	332.93		0.003
Ethanol (L)	(%v/v)	1.45	(1.20 - 1.70)	1.09	(1.00- 1.16)	1.3	1.33	1.00	0.690
Ethanol (L)	(%v/v)	1.75	(1.51 - 2.02)	1.20	(1.06 - 1.36)	1.5	1.46	0.60	0.343
Ethanol (L)	(%v/v)	1.99	(1.91 - 2.09)	1.06	(0.94 - 1.19)	1.9	1.88	0.60	0.302
Ethanol (L)	(%v/v)	1.78	(1.74 - 1.81)	1.04	(0.98 - 1.10)	1.7	1.71	0.60	0.337
Ethanol (L)	(%v/v)	1.44	(1.20 - 1.71)	1.01	(0.95 - 1.09)	1.4	1.43	1.00	0.694

Substance	FETAX Malformations	Reference
2,4-D// 2,4-dichlorophenoxyacetic acid		Dawson and Bantle (1987)
Diethylene glycol	Mo, Se at MAS 96h EC50; Se, Sl, Mo at MAS 96h LC50; GM, FA, OC, HA were all common; Ed, NM were rare	Dawson and Bantle (1987)
Diethylene glycol	Mo, Se at MAS 96h EC50; Se, Sl, Mo at MAS 96h LC50; GM, FA, OC, HA were all common; Ed, NM were rare	Dawson and Bantle (1987)
Diethylene glycol	Mo, Se at MAS 96h EC50; Se, Sl, Mo at MAS 96h LC50; GM, FA, OC, HA were all common; Ed, NM were rare	Dawson and Bantle (1987)
Dimethyl sulfoxide// DMSO		Courchesne, CL, and JA Bantle
Diphenhydramine hydrochloride// Benadryl [registered]		Dawson et al. (1991)
Diphenylamine//N-phenylbenzeneamine	mal-developed gut, visceral hemorrhage, muscular kinking	Bantle et al. (1998? rpt)
Doxylamine succinate		Bantle et al. (1998? rpt)
Ethanol (L)	Severity of malformations increased with concentration; AE just above 96h LC50	Bantle et al. (1998? rpt)
Ethanol (L)	Severity of malformations increased with concentration; AE just above 96h LC50	Fort et al. (1991)
Ethanol (L)	Severity of malformations increased with concentration; AE just above 96h LC50	Bantle et al. (1994b)
Ethanol (L)	Severity of malformations increased with concentration; AE just above 96h LC50	Bantle et al. (1994b)
Ethanol (L)	Severity of malformations increased with concentration; AE just above 96h LC50	Bantle et al. (1994b)